General AML

Jan Cornelissen | EHA 2018 | Panobinostat, decitabine & DLI post-allo HSCT in ND poor-risk AML patients 

L:

23rd Congress of the European Hematology Association, 14-17 June 2018, Stockholm, Sweden

Jan Cornelissen: Erasmus University Medical Center, Rotterdam, NL

Interview topic: Panobinostat, decitabine and DLI post-allogeneic HSCT in ND poor-risk AML patients

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF